Can probiotics help tame fatty liver? new study seeks answers
NCT ID NCT07400367
First seen Feb 13, 2026 · Last updated Jun 19, 2026 · Updated 17 times
Summary
This study is testing whether a multi-strain probiotic supplement, taken alongside standard lifestyle advice, can improve liver health in people with Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD). The trial will enroll 80 adults with elevated liver enzymes and fatty liver. Participants will receive either the probiotic or a placebo for 12 weeks, and researchers will measure changes in liver stiffness (fibrosis) and fat content, as well as blood sugar and cholesterol levels.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for INSULIN RESISTANCE are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Fu Jen Catholic University Hospital
NOT_YET_RECRUITINGNew Taipei City, Taiwan
-
Fu Jen Catholic University Hospital
RECRUITINGNew Taipei City, Taiwan
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
multi-strain probiotic (Lactobacillus salivarius AP-32, Lactobacillus rhamnosus bv-77, Bifidobacterium animalis CP-9, Lactobacillus reuteri GL-104)
What this could lead to
If it works, this could point toward a simple, safe add-on treatment to help manage MASLD and reduce liver damage.
What could go wrong
This is a small, early-stage trial (80 people) testing a dietary supplement, not a drug. Results may not be dramatic or apply to everyone. The main benefit may come from the lifestyle changes, not the probiotic itself.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.